It's obviously ok when they do it @sarge17 ... lol
Has anyone seen that "shareholder value" created that the new CEO promised in her webinar earlier in the year ? The share price has decreased by basically another 50% since Cheryl took the reins ... and many scoffed at a 30-50 cent takeover being accepted in the last 12 months when I posted it on here ? It's looking pretty good now IMO
Sadly, the reality is that JF & Co. took far too long with the DEP trials and newer and better treatments have emerged making the DEP drugs we trialed obsolete in the oncology space... the best we can probably hope for is a big pharma wanting the DEP tech and taking advantage of the severely depressed market cap in a takeover scenario. At least big pharma will have the resources (both financial and human) to apply the DEP tech to a multitude of drugs and actually get them to market if they see success / improvements.
GLTAH
SPL Price at posting:
9.7¢ Sentiment: Hold Disclosure: Held
